Literature DB >> 9669190

Antidepressant interactions with warfarin.

D Duncan1, K Sayal, H McConnell, D Taylor.   

Abstract

The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different classes of antidepressants are discussed in turn. The possible mechanisms are considered with particular reference to the cytochrome p450 system. From currently available data on the newer antidepressants our conclusions are that citalopram, nefazodone and sertraline may be relatively less likely to interact with warfarin. Fluoxetine, fluvoxamine, paroxetine and moclobemide appear to have the highest potential of the antidepressants for interactions. There is insufficient data on venlafaxine to make a prediction. The clinical implications of these findings are discussed and specific recommendations for International Normalized Ratio monitoring are suggested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669190     DOI: 10.1097/00004850-199803000-00006

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  9 in total

Review 1.  Drug interactions update: drugs, herbs, and oral anticoagulation.

Authors:  A K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

Review 2.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

3.  Bleeding incidence with concomitant use of antidepressants and warfarin.

Authors:  Kelly A Cochran; Larisa H Cavallari; Nancy L Shapiro; Jeffrey R Bishop
Journal:  Ther Drug Monit       Date:  2011-08       Impact factor: 3.681

4.  Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment.

Authors:  Martina Teichert; Loes E Visser; Andrė G Uitterlinden; Albert Hofman; Peter J Buhre; Sabine Straus; Peter A G M De Smet; Bruno H Stricker
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

5.  Warfarin toxicity and individual variability-clinical case.

Authors:  Irina Piatkov; Colin Rochester; Trudi Jones; Steven Boyages
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

6.  Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial.

Authors:  Maria Paile-Hyvärinen; Kristian Wahlbeck; Johan G Eriksson
Journal:  BMC Fam Pract       Date:  2003-05-14       Impact factor: 2.497

7.  Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial.

Authors:  Maria Paile-Hyvärinen; Kristian Wahlbeck; Johan G Eriksson
Journal:  BMC Fam Pract       Date:  2007-06-15       Impact factor: 2.497

8.  Bupropion-warfarin combination: a serious complication.

Authors:  Amar D Bavle; Akshay S Phatak
Journal:  Indian J Psychol Med       Date:  2013-07

9.  Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Jin Ah Jung; Soo-Yun Lee; Tae-Eun Kim; Jung-Ryul Kim; Chin Kim; Wooseong Huh; Jae-Wook Ko
Journal:  Drug Des Devel Ther       Date:  2015-03-02       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.